NanoViricides, Inc. entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC on July 17, 2026, allowing the company to offer and sell common stock through an at-the-market offering. The company will pay a 2.0% commission to the Sales Agent for each sale of shares. NanoViricides, Inc. is a biotechnology company focused on developing antiviral-based therapeutics.
